Trial · NCT01147666
Results by group327
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 327
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | 4 | Participants | ||
| Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | 8 | Participants | ||
| Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | 7 | Participants | ||
| Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | 4 | Participants | ||
| Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only | Cohort A (Epoetin Alfa) | 3 | Participants | ||
| Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Hyporesponsive Participants Treated for at Least 6 Weeks | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | 0 | Participants | ||
| Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Hyporesponsive Participants Treated for at Least 6 Weeks | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | 1 | Participants | ||
| Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Hyporesponsive Participants Treated for at Least 6 Weeks | Cohort B (Epoetin Alfa) | 2 | Participants | ||
| Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Hyporesponsive Participants Treated for at Least 6 Weeks | Cohort B (Placebo) | 0 | Participants | ||
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | 4 | Participants | ||
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | 4 | Participants | ||
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | 6 | Participants | ||
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | 5 | Participants | ||
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | 6 | Participants | ||
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | Cohort A-9 (Roxadustat 2.0 mg/kg) | 2 | Participants | ||
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | 4 | Participants | ||
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | Cohorts A (Epoetin Alfa) | 8 | Participants | ||
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | 0 | Participants | ||
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | Cohort B (Epoetin Alfa) | 0 | Participants | ||
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | Cohort B (Placebo) | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01147666/results